Seelaus Asset Management LLC Sells 426 Shares of Eli Lilly and Company (NYSE:LLY)

Seelaus Asset Management LLC lessened its position in Eli Lilly and Company (NYSE:LLYFree Report) by 47.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 465 shares of the company’s stock after selling 426 shares during the quarter. Seelaus Asset Management LLC’s holdings in Eli Lilly and Company were worth $362,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $5,992,890,000. International Assets Investment Management LLC boosted its stake in Eli Lilly and Company by 61,268.8% in the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after buying an additional 7,330,815 shares in the last quarter. Sapient Capital LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at $682,139,000. Vanguard Group Inc. grew its position in Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after acquiring an additional 659,838 shares during the period. Finally, Comerica Bank bought a new position in Eli Lilly and Company in the 3rd quarter valued at $345,781,000. 82.53% of the stock is currently owned by institutional investors.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 92,563 shares of the firm’s stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the sale, the insider now owns 98,556,247 shares in the company, valued at $79,752,700,634.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, major shareholder Lilly Endowment Inc sold 92,563 shares of the firm’s stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the transaction, the insider now directly owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Insiders have sold 858,742 shares of company stock valued at $735,573,781 over the last three months. 0.13% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on LLY shares. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Citigroup upped their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. The Goldman Sachs Group boosted their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. BMO Capital Markets reaffirmed an “outperform” rating and set a $1,001.00 price target on shares of Eli Lilly and Company in a report on Wednesday, July 3rd. Finally, Jefferies Financial Group raised their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $816.78.

Get Our Latest Stock Report on Eli Lilly and Company

Eli Lilly and Company Stock Up 0.6 %

LLY stock opened at $919.95 on Monday. The company has a market cap of $874.33 billion, a P/E ratio of 134.69, a price-to-earnings-growth ratio of 1.99 and a beta of 0.41. The stock’s 50 day simple moving average is $831.69 and its 200 day simple moving average is $752.53. Eli Lilly and Company has a fifty-two week low of $434.34 and a fifty-two week high of $919.95. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.62 EPS. On average, research analysts expect that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.57%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is 76.58%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Articles

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.